lys-pro-arg-arg-pro-tyr-vip(7-28) profile

(VIP-neurotensin) hybrid antagonist: contains fractions of VIP peptide & neurotensin; 28 amino acid sequence given in first source; consists of an N-terminal sequence from neurotensin and the 22 C-terminal amino acids of vasoactive intestinal peptide (VIP); inhibits VIP receptor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	102602038
MeSH ID	M0188922

Synonym
125093-93-8
(lys(1)-pro(2,5)-arg(3,4)-tyr(6))vip(7-28)
viphyb
vip-ne hybrid antag
vasoactive intestinal octacosapeptide (pig), 1-l-lysine-2-l-proline-3-l-arginine-4-l-arginine-5-l-proline-6-l-tyrosine-
neurotensin(6-11)vip(7-28)
lys-pro-arg-arg-pro-tyr-vip(7-28)
(vip-neurotensin) hybrid antagonist
lysyl-prolyl-arginyl-arginyl-prolyl-tyrosyl-vip(7-28)
vip antagonist
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-ser-ile-leu-asn-nh2
mfcd00080365
h-lys-pro-arg-arg-pro-tyr-thr-asp-asn-tyr-thr-arg-leu-arg-lys-gln-met-ala-val-lys-lys-tyr-leu-asn-se

Excerpt	Relevance	Reference
" In contrast, PHI was an effective stimulant in doses up to 15 nmol/rat but had no effect on either ACTH or CORT at a dose of 30 nmol/rat thus yielding a bell-shaped dose-response curve."	( VIP antagonist demonstrates differences in VIP- and PHI-mediated stimulation and inhibition of ACTH and corticosterone secretion in rats. Alexander, LD; Sander, LD, 1995)	0.29

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	6 (37.50)	18.2507
2000's	4 (25.00)	29.6817
2010's	6 (37.50)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	17 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
corticosterone [no description available]	1.98	1	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone	human metabolite; mouse metabolite
thymidine [no description available]	2	1	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; metabolite; mouse metabolite
trinitrobenzenesulfonic acid Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.	2.03	1	arenesulfonic acid; C-nitro compound	epitope; explosive; reagent
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	2.17	1	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
ro 25-1553 Ro 25-1553: a cyclic peptide analog and agonist of vasoactive intestinal peptide; a VPAC(2) receptor agonist; amino acid sequence given in first source	1.99	1
peptide phi Peptide PHI: A 27-amino acid peptide with histidine at the N-terminal and isoleucine amide at the C-terminal. The exact amino acid composition of the peptide is species dependent. The peptide is secreted in the intestine, but is found in the nervous system, many organs, and in the majority of peripheral tissues. It has a wide range of biological actions, affecting the cardiovascular, gastrointestinal, respiratory, and central nervous systems.	1.98	1
glucagon-like peptide 1 Glucagon-Like Peptide 1: A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.	2.07	1
vasoactive intestinal peptide (10-28) vasoactive intestinal peptide (10-28): inhibits VIP stimulation of adenylate cyclase	1.98	1
exendin (9-39) exendin (9-39): a peptide from the venom of the lizard Heloderma suspectum; inhibits glucagon-like peptide-1 (GLP-1) induced cAMP production; its structure is related to exendin-4	2.07	1
neurotensin neurotensin, Tyr(11)-: RN given refers to parent cpd & (D)-isomer; RN for cpd without isomeric designation not avail 5/91	4.16	16	peptide hormone	human metabolite; mitogen; neurotransmitter; vulnerary
vasoactive intestinal peptide Vasoactive Intestinal Peptide: A highly basic, 28 amino acid neuropeptide released from intestinal mucosa. It has a wide range of biological actions affecting the cardiovascular, gastrointestinal, and respiratory systems and is neuroprotective. It binds special receptors (RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE).	4.16	16
vasoactive intestinal peptide, 4-chloro-phe(6)-leu(17)- vasoactive intestinal peptide, 4-chloro-Phe(6)-Leu(17)-: VIP receptor antagonist	1.98	1
glucagon-like peptide 2 Glucagon-Like Peptide 2: A 33-amino acid peptide derived from the C-terminal of PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. It stimulates intestinal mucosal growth and decreased apoptosis of ENTEROCYTES. GLP-2 enhances gastrointestinal function and plays an important role in nutrient homeostasis.	2.46	2

Condition	Relationship Strength	Studies
Germinoblastoma [description not available]	2.17	1
Diffuse Large B-Cell Lymphoma [description not available]	2.17	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.17	1
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	2.17	1
Cytomegalic Inclusion Disease [description not available]	2.08	1
Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults.	2.08	1
Cytomegalovirus A genus of the family HERPESVIRIDAE, subfamily BETAHERPESVIRINAE, infecting the salivary glands, liver, spleen, lungs, eyes, and other organs, in which they produce characteristically enlarged cells with intranuclear inclusions. Infection with Cytomegalovirus is also seen as an opportunistic infection in AIDS.	2.08	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.08	1
Anxiety Feelings or emotions of dread, apprehension, and impending disaster but not disabling as with ANXIETY DISORDERS.	2.08	1
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	2.1	1
Graft-Versus-Host Disease [description not available]	2.08	1
B Virus Infection [description not available]	2.08	1
Graft vs Host Disease The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.	2.08	1
Colitis Gravis [description not available]	2.03	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.42	2
Ileitis Inflammation of any segment of the ILEUM and the ILEOCECAL VALVE.	2.03	1
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.03	1
Tachyarrhythmia [description not available]	1.98	1
Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.	1.98	1
Carcinoma, Non-Small Cell Lung [description not available]	2.4	2
Cancer of Lung [description not available]	2.4	2
Experimental Neoplasms [description not available]	1.98	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.4	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.4	2
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	1.99	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.4	2
Delayed Effects, Prenatal Exposure [description not available]	1.99	1
Breast Cancer [description not available]	2	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2	1
Astrocytoma, Grade IV [description not available]	2	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2	1

lys-pro-arg-arg-pro-tyr-vip(7-28)

Description

Cross-References

Synonyms (13)

Research Excerpts

Dosage Studied

Research

Studies (16)

Market Indicators

Research Demand Index: 11.69

Study Types